<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and FK-565 in up-regulation of lymphokine-activated killer (LAK) cell induction by IL-2 was examined </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment of blood mononuclear cells (MNC) of healthy donors with <z:chebi fb="2" ids="27899">cisplatin</z:chebi> or FK-565 in the presence of IL-2 resulted in a significant increase in LAK activity against natural killer (NK)-resistant Daudi cells as assessed by the 4 h <z:chebi fb="0" ids="50076">51Cr</z:chebi> release assay </plain></SENT>
<SENT sid="2" pm="."><plain>Blood MNC treated with <z:chebi fb="2" ids="27899">cisplatin</z:chebi> alone was not cytotoxic to Daudi cells </plain></SENT>
<SENT sid="3" pm="."><plain>However, MNC treated with FK-565 showed some cytotoxicity against Daudi cells </plain></SENT>
<SENT sid="4" pm="."><plain>Addition of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> to IL-2-stimulated MNC did not increase proliferation but did enhance cytotoxicity </plain></SENT>
<SENT sid="5" pm="."><plain>FK-565 together with IL-2 increased both proliferation and cytotoxicity of blood MNC </plain></SENT>
<SENT sid="6" pm="."><plain>These data suggest the potential of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and FK-565 in LAK adoptive immunotherapy for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
</text></document>